Protocol 014 was a phase-II HIV vaccine trial that consisted of two
vaccines: one was made to look like gp120, a protein found
in the coat that surrounds the virus, and the other vaccine had HIV genes
engineered into a live canarypox virus (which does not
reproduce in humans). The 014 trial was a safety trial which means we
did not know whether this vaccine would protect people
from HIV. In this phase-II trial we were evaluating the type and extent of
immune response people have to the combination
approach (two vaccines) and attempting to determine if this vaccine
combination approach is appropriate for further testing.
Here at the
Seattle HPTU site we contacted participants from our previous study, "Be a
Hero," (Vaccine Preparedness Study or "VPS"),
to learn about this study and 30 men were subsequently enrolled. Our
efforts locally were joined by seven other HPTU sites as
well as six HIV Vaccine Trials Unit (HVTU) sites around the country for a
total of 420 study participants. This study is now complete, and our
volunteers are currently in long-term follow-up.
What were the findings?
The vaccines were shown to be well-tolerated by study volunteers. Immune response
was produced in the majority of volunteers who received the canary-pox vaccine.
How can I get more information?
If you have further questions about this or any of our research studies, feel
free to contact us. You can also click on the
links below to read the abstracts of the journal article that was written
based on data gathered during the Phase II 014 Vaccine trial:
- Safety and immunogenicity of a canarypox-vectored
human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study
in higher- and lower-risk volunteers
We are no longer enrolling for this study, but if you are interested
in participating in HIV prevention research, please explore our research
page that lists studies that we are currently enrolling for.
Thank You
to all of our
Vaccine Trial
Volunteers!
